Nektar Therapeutics is a biopharmaceutical company developing novel cancer therapies. Their lead immuno-oncology candidate is an immuno-stimulatory CD-122 biased cytokine which is currently in human clinical studies. Further information about the company and its drug development programs may be found online at http://www.nektar.com